Liver Cancer Drugs Market - 42% of Growth to Originate from North America | Evolving Opportunities with AstraZeneca Plc & Bayer AG| 17000+ Technavio Reports

For more insights on the market share of various regions - Download a free sample now!

Market Dynamics

Factors such as the increasing incidence of liver cancer, advancements in diagnostic methods will be crucial in driving the growth of the market. But factors such as the only curative option available is surgical resection and transplantation will restrict the market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Company Profiles

 The liver cancer drugs market is fragmented and the vendors are deploying growth strategies such as acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share to competitors in the market. The liver cancer drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc.

Few companies with key offerings

• AstraZeneca Plc - The company offers Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
• Bayer AG - The company offers drugs, treatment, and diagnoses for liver cancer.
• Eli Lilly and Co.- The company offers CYRAMZA for the treatment of lung, liver, stomach, and colorectal cancers.
• Gilead Sciences Inc. - The company offers a wide range of drugs for the treatment of liver diseases such as Epclusa, Harvoni, Hepsera, and others.
• Lion TCR Pte. - The company offers LioCyx-M004 drugs for the treatment of Hepatocellular Carcinoma which is one of the types of liver cancer.
• To know more about more vendors with offerings - Download a free sample report now!

Competitive Analysis

The competitive scenario provided in the liver cancer drugs market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Segmentation

• By Type, the market is classified as immunotherapy and targeted therapy.
• By Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW). 

To know about the market contribution of each segment - Download a free sample now!

Related Reports -

• The non-small cell lung cancer drugs market share is expected to increase by USD 30.23 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 17.1%. Download a free sample now!
• The cancer therapies market in Europe is expected to increase by USD 34.71 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.92%. Download a free sample now!

Table of Content

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Immunotherapy - Market size and forecast 2021-2026
• Exhibit 28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)

• 5.4 Targeted therapy - Market size and forecast 2021-2026
• Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AstraZeneca Plc
• Exhibit 85: AstraZeneca Plc - Overview
• Exhibit 86: AstraZeneca Plc - Product / Service
• Exhibit 87: AstraZeneca Plc - Key news
• Exhibit 88: AstraZeneca Plc - Key offerings

• 10.4 Bayer AG
• Exhibit 89: Bayer AG - Overview
• Exhibit 90: Bayer AG - Business segments
• Exhibit 91: Bayer AG - Key news
• Exhibit 92: Bayer AG - Key offerings
• Exhibit 93: Bayer AG - Segment focus

• 10.5 Bristol-Myers Squibb Co.
• Exhibit 94: Bristol-Myers Squibb Co. - Overview
• Exhibit 95: Bristol-Myers Squibb Co. - Product / Service
• Exhibit 96: Bristol-Myers Squibb Co. - Key offerings

• 10.6 Eisai Co. Ltd.
• Exhibit 97: Eisai Co. Ltd. - Overview
• Exhibit 98: Eisai Co. Ltd. - Business segments
• Exhibit 99: Eisai Co. Ltd. - Key offerings
• Exhibit 100: Eisai Co. Ltd. - Segment focus

• 10.7 Eli Lilly and Co.
• Exhibit 101: Eli Lilly and Co. - Overview
• Exhibit 102: Eli Lilly and Co. - Business segments
• Exhibit 103: Eli Lilly and Co. - Key offerings
• Exhibit 104: Eli Lilly and Co. - Segment focus

• 10.8 Eureka Therapeutics
• Exhibit 105: Eureka Therapeutics - Overview
• Exhibit 106: Eureka Therapeutics - Product / Service
• Exhibit 107: Eureka Therapeutics - Key offerings

• 10.9 Gilead Sciences Inc.
• Exhibit 108: Gilead Sciences Inc. - Overview
• Exhibit 109: Gilead Sciences Inc. - Business segments
• Exhibit 110: Gilead Sciences Inc. - Key news
• Exhibit 111: Gilead Sciences Inc. - Key offerings
• Exhibit 112: Gilead Sciences Inc. - Segment focus

• 10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
• Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
• Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings

• 10.11 Lion TCR Pte. Ltd
• Exhibit 116: Lion TCR Pte. Ltd - Overview
• Exhibit 117: Lion TCR Pte. Ltd - Product / Service
• Exhibit 118: Lion TCR Pte. Ltd - Key offerings

• 10.12 Merck and Co. Inc.
• Exhibit 119: Merck and Co. Inc. - Overview
• Exhibit 120: Merck and Co. Inc. - Business segments
• Exhibit 121: Merck and Co. Inc. - Key news
• Exhibit 122: Merck and Co. Inc. - Key offerings
• Exhibit 123: Merck and Co. Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations
• Exhibit 130: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio